

LoopLab

LOOP LAB

Transforming Immunotherapy Through Targeted Immune Tolerance



EXPERIENCED & SUCCESSFUL TEAM

Experienced team of successful biotech veterans and scientific experts will rapidly demonstrate proof-of-concept with a clear path to first-in-human studies



PROPRIETARY TECHNOLOGY (ROBUST IP)

Exclusively owned, proprietary, Fc-Engager technology is designed to induce antigen-specific immune tolerance with high potency and durability



INNOVATION WITH GLOBAL IMPACT

Novel platform and transformative approach addresses current challenges in treating allergies, autoimmune, and immune-related diseases



EXPANSIVE MARKET POTENTIAL

Modular platform design enables scalability for new disease targets to feed LoopLab's own pipeline and that of potential partners



INDEPENDENTLY FUNDED

Seed funding in place to reach multiple value inflection points in the next 12-18 months

Unmet Clinical Needs in High-Value Immune Therapies


- Gaps in current therapy due to lack of specificity
- Opportunity for new therapy (\$200B SAM)

Re-Educating the immune system - Not Suppressing it


Disease Burden:

- up to 800 Mio Auto-Immune Disease Patients
- > 1 Bio People with Allergies

CURRENT THERAPIES




LOOPLAB SOLUTION



The "Swiss Army Knife" to Immune Tolerance

1. ENGAGING INHIBITORY (Fc)-RECEPTORS ON IMMUNE CELLS
2. CROSSLINKS INHIBITORY Fc-RECEPTORS TO B-CELL RECEPTORS
3. UNLOCKS TOLERANCE INDUCTION ON DISEASED CELLS



Achieving Comprehensive Immune Tolerance via B-Cells, Basophils & Mast Cells, and Liver Cells

B-cells

- Crosslinks inhibitory Fc-receptor and BCRs
- Induces inhibitory signaling


Basophils & Mast cells

- Crosslinks inhibitory Fc-receptor and FcER1
- Strongly inhibits basophil & mast cell activation
- Minimizes release of inflammatory mediators


Liver Cells (LSECs)

- Captures autoantibodies
- Contributes to removal of immune complexes
- Shuttles captured Abs to liver

TOLEROGENIC FC-ENGAGERS DEMONSTRATE FUNCTIONALITY IN PRIMARY HUMAN BASOPHILS



ANTIGEN-SPECIFIC PREVENTION OF B-CELL RESPONSE IN VIVO




Fc-Engager's Innovative Mechanism uniquely harnesses inhibitory Fc receptors to reprogram immune tolerance.

Data Highlights:

- **Molecular:** Specific binding to and signaling via inhibitory Fc-receptors
- **Cellular:** Significant reduction in mast cell and basophil activation
- **In vivo:** Suppression of antigen-specific antibody production

High-Specificity Tolerance Induction: LoopLab's Differentiated Fc Engineering


High Specificity / Tolerance Induction



A First-in-Class Therapeutic Platform for Autoimmune Diseases



LoopLab's Strategic and Focused Development Plan to FiH



Experiences and successful leadership



Jochen Stritzker, PhD

- CEO/CSO & Co-founder
- 20+ years in Biotech & Pharma (Europe & US) including 15+ years in managerial roles
- Previous companies: Genelux (IPO), Themis (acquired by MSD), Merck (US)
- Numerous publications & patents
- **Key achievement:** MSD acquisition of Themis (worked on) – now "doing it again" at LoopLab



Simona Neubauer, Mag., MBA

- COO & Co-founder
- 15+ years in Biotech & Pharma
- Previous companies: Baxter, Alcon, Kwizda Pharmadistribution, Themis
- Extensive expertise in Quality Assurance and Operations
- **Key achievement:** Part of Themis team during successful acquisition by MSD



Eva Mihailovska, PhD

- CDO
- 15+ years in Biotech & Pharma
- Previous companies: Evotec, Valneva, AFFIRIS AG
- Numerous publications & patents
- **Key achievements:** Out-licensing Affiris vaccines to AC Immune, Valneva vaccine out-licensed to Pfizer, Global project lead at Evotec



Andrea Vogel, PhD

- Head of Research
- Academic track record
- PhD in immunology
- Numerous publications

MAJOR OUT-LICENSING POTENTIAL



ALLERGIES



ANTI-DRUG ANTIBODIES



BULLOUS PEMPHIGOID



CELIAC DISEASE



Liz Leveille
VP Boston & European Innovation Hubs, MSD



Bernd Jilma
Prof., Medical University Vienna



Oscar Izeboud
CEO, Scenic Biotech



Gordana Wozniak-Knopp
Prof., BOKU Vienna (Yeast library screen (FFG-funded project))



Falk Nimmerjahn
Prof., Univ. Erlangen-Nuremberg (Fc-receptor expert)



Enno Schmid
Prof., Univ. Lübeck (expert on autoimmune disease of the skin)



Bart Lambrecht
Prof., Univ. Ghent (Fc-receptor & allergy expert)



Friedrich Scheiflinger
FS Pharma Consulting GmbH; Biotech & Pharma Executive

[http://](http://www.looplab.bio)

[WWW.LOOLAB.BIO](http://www.looplab.bio)

CONTACT:
SIMONA NEUBAUER COO
PHONE +43 12367151
MOBILE +43 676 8434 96 771
SIMONA.NEUBAUER@LOOLAB.BIO